Candel Therapeutics, Inc. 8-K

What Happened
Candel Therapeutics, Inc. (CADL) announced its financial results for the quarter ended March 31, 2026. The company furnished a press release dated May 14, 2026 as Exhibit 99.1 to a Current Report on Form 8‑K (filed May 14, 2026) to disclose its quarterly results and related information.

Key Details

• Event reported under Item 2.02 (Results of Operations and Financial Condition) of Form 8‑K.
• Press release dated May 14, 2026 is furnished as Exhibit 99.1 to the filing.
• The filing states the furnished information (including Exhibit 99.1) is “furnished” and not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except where expressly stated.
• The Form 8‑K was signed by President and CEO Paul Peter Tak, M.D., Ph.D., FMedSci.

Why It Matters
This 8‑K signals that Candel has publicly released its quarterly earnings and related operational information; investors should review the May 14 press release (Exhibit 99.1) for specific financial figures (revenue, cash position, operating expenses) and any commentary on business progress or guidance. The legal note that the release is “furnished” (not “filed”) affects certain liability and incorporation-by-reference implications for future SEC filings.